Spots Global Cancer Trial Database for colorectal cancer (crc)
Every month we try and update this database with for colorectal cancer (crc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Prevention of Colorectal Cancer Through Multiomics Blood Testing | NCT04369053 | Colon Cancer Rectal Cancer Colon Neoplasm Colon Diseases Colon Lesion Colon Polyp Colorectal Canc... Polyp Adenoma Rectal Diseases Gastrointestina... | Freenome test | 45 Years - 85 Years | Freenome Holdings Inc. | |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | NCT02955940 | Pancreatic Canc... Colorectal Canc... Breast Cancer Lung Cancer | Ruxolitinib Capecitabine Regorafenib | 18 Years - | Incyte Corporation | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| A Study of SC-007 in Subjects With Advanced Cancer | NCT03253185 | Colorectal Canc... Gastric Cancer | SC-007 | 18 Years - | AbbVie | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | NCT03082209 | Advanced Solid ... Cancer Hematologic Mal... | ABBV-621 Venetoclax Bevacizumab FOLFIRI | 18 Years - | AbbVie | |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | NCT03314935 | Biliary Tract C... Colorectal Canc... Endometrial Can... Gastroesophagea... Ovarian Cancer Solid Tumors | INCB001158 Oxaliplatin Leucovorin 5-Fluorouracil Gemcitabine Cisplatin Paclitaxel | 18 Years - | Incyte Corporation | |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | NCT02955940 | Pancreatic Canc... Colorectal Canc... Breast Cancer Lung Cancer | Ruxolitinib Capecitabine Regorafenib | 18 Years - | Incyte Corporation | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | NCT02646748 | Colorectal Canc... Endometrial Can... Melanoma Head and Neck C... Lung Cancer MMR-deficient T... Breast Cancer Pancreatic Canc... Renal Cell Carc... Solid Tumors UC (Urothelial ... | Pembrolizumab itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | NCT05919264 | Cancer Colorectal Canc... Solid Tumor Locally Advance... Metastatic Canc... Gastric Cancer Non-small Cell ... Non-small Cell ... Non-small Cell ... Non-small Cell ... Non-Small Cell ... Gastroesophagea... WNT Pathway β-catenin Beta-catenin Adenomatous Pol... APC | FOG-001 FOG-001 | 18 Years - | Fog Pharmaceuticals, Inc. | |
| Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer | NCT00851045 | Colorectal Canc... | Irinotecan 5-Fluorouracil ... 5-Fluorouracil ... Leucovorin calc... CT-322 Bevacizumab Bevacizumab Pla... | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | NCT03361228 | Solid Tumors | INCB001158 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | NCT06179160 | Solid Tumors | INCB161734 Cetuximab Retifanlimab | 18 Years - | Incyte Corporation | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) | NCT00483080 | Colorectal Canc... | NGR-hTNF | 18 Years - 80 Years | AGC Biologics S.p.A. | |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | NCT05277051 | Neoplasms | GSK4381562 Dostarlimab GSK4428859A | 18 Years - | GlaxoSmithKline | |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | NCT04256707 | Non-Small Cell ... Colorectal Canc... Other Solid Tum... | Selinexor 100 m... Docetaxel Pembrolizumab FOLFIRI Selinexor 40 mg Selinexor 80 mg Selinexor 60 mg | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | NCT05706129 | Clear Cell Rena... Pancreatic Duct... Colorectal Canc... | [68Ga]Ga-DPI-44... [177Lu]Lu-DPI-4... | 18 Years - | Debiopharm International SA | |
| Adherence and the Economics of Colon Cancer Screening | NCT00705731 | Colorectal Canc... | 50 Years - 79 Years | University of California, San Francisco | ||
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | NCT03811652 | Non Small Cell ... Head and Neck S... Small Cell Lung... Pancreatic Duct... Colorectal Canc... Metastatic Cast... | MEDI7247 | 18 Years - 101 Years | MedImmune LLC | |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | NCT02327078 | B-cell Malignan... Colorectal Canc... Head and Neck C... Lung Cancer Lymphoma Melanoma Ovarian Cancer Glioblastoma | Nivolumab Epacadostat Chemotherapy | 18 Years - | Incyte Corporation | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | NCT06131398 | Advanced Solid ... | AMG 355 Pembrolizumab | 18 Years - 100 Years | Amgen | |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor | NCT05262491 | Gastrointestina... | BL-B01D1 | 18 Years - 75 Years | Sichuan Baili Pharmaceutical Co., Ltd. | |
| A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence | NCT02005913 | Colorectal Canc... | 20 Years - | National Taiwan University Hospital | ||
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | NCT02955940 | Pancreatic Canc... Colorectal Canc... Breast Cancer Lung Cancer | Ruxolitinib Capecitabine Regorafenib | 18 Years - | Incyte Corporation | |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | NCT05706129 | Clear Cell Rena... Pancreatic Duct... Colorectal Canc... | [68Ga]Ga-DPI-44... [177Lu]Lu-DPI-4... | 18 Years - | Debiopharm International SA | |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | NCT03565003 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) | NCT00483080 | Colorectal Canc... | NGR-hTNF | 18 Years - 80 Years | AGC Biologics S.p.A. | |
| Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients | NCT00977613 | Colorectal Canc... | exercise counse... | - | Beth Israel Medical Center | |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | NCT03314935 | Biliary Tract C... Colorectal Canc... Endometrial Can... Gastroesophagea... Ovarian Cancer Solid Tumors | INCB001158 Oxaliplatin Leucovorin 5-Fluorouracil Gemcitabine Cisplatin Paclitaxel | 18 Years - | Incyte Corporation | |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | NCT03565003 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer | NCT00165854 | Colorectal Canc... | E7070 | 18 Years - | Eisai Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
